Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T18:48:29.407Z Has data issue: false hasContentIssue false
  • English
  • Français

WCA Recommendations for the Long-Term Treatment of Anxiety Disorders

Published online by Cambridge University Press:  07 November 2014

Joseph Zohar
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
CNS Spectrums , Volume 8 , supplement S1: Recommendations for the Long-Term Treatment of Anxiety Disorders , August 2003 , pp. 5 - 6
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Skaer, TL, Robison, LM, Sclar, DA, et al.Anxiety disorders in the USA, 1990 to 1997. Trends in complaint, diagnosis, use of pharmacotherapy and diagnosis of comorbid depression. Clin Drug Invest. 2000;20:237–244.CrossRefGoogle Scholar
2.Greenberg, PE, Sisitsky, T, Kessler, RC, et al.The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427–435.CrossRefGoogle ScholarPubMed
3.Katz, RJ, DeVeaugh-Geiss, J, Landau, P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990;28:401–414.CrossRefGoogle ScholarPubMed
4.Tollefson, GD, Birkett, M, Koran, L, et al.Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55(suppl):69–76.Google ScholarPubMed
5.Romano, S, Goodman, W, Tamura, R, et al.Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001;21:46–52.CrossRefGoogle ScholarPubMed
6.Cottraux, J, Mollard, E, Bouvard, M, et al.A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1990;5:17–30.CrossRefGoogle ScholarPubMed
7.Mallya, GK, White, K, Waternaux, C, et al.Short- and long-term treatment of obsessive-compulsive disorder with Fluvoxamine. Ann Clin Psychiatry. 1992;4:77–80.CrossRefGoogle Scholar
8.Greist, JH, Jefferson, JW, Kobak, KA, et al.A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995; 10:57–65.CrossRefGoogle ScholarPubMed
9.Rasmussen, S, Hackett, E, DuBoff, E, et al.A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12:309–316.CrossRefGoogle ScholarPubMed
10.Koran, LM, Robinson, DG, Hackett, E, Rubin, A, Wolkow, RM. Efficacy of sertraline in long-term OCD treatment: preliminary results of a multicenter study. Abstract presented at: Annual Meeting of the American Psychiatric Association; Washington, DC; May 15–20, 1999.Google Scholar
11.Bergeron, R, Hadrava, V, Ravindran, AV. Sertraline and fluoxetine treatment of OCD: a six-month, double-blind, parallel study. Poster presented at: 13th Annual Congress of the European College of Neuropsychopharmacology; September 9–13, 2000; Munich, Germany.Google Scholar
12.Lepola, UM, Wade, AG, Leinonen, EV, et al.A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998;59:528–534.CrossRefGoogle ScholarPubMed
13.Fahy, TJ, O'Rourke, D, Brophy, J, et al.The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord. 1992;25:63–75.CrossRefGoogle ScholarPubMed
14.Michelson, D, Pollack, M, Lydiard, RB, et al.Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999;174:213–218.CrossRefGoogle ScholarPubMed
15.Lydiard, RB, Steiner, M, Burnham, D, et al.Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull. 1998;34:175–182.Google ScholarPubMed
16.Lecrubier, Y, Judge, R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:153–160.CrossRefGoogle ScholarPubMed
17.Rapaport, MH, Wolkow, R, Rubin, A, Hackett, E, Pollack, M, Ota, KY. Sertraline treatment in panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001;104:289–298.CrossRefGoogle ScholarPubMed
18.Londborg, PD, Hegel, MT, Goldstein, S, et al.Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001;62:325–331.CrossRefGoogle ScholarPubMed
19.Davidson, JR, Rothbaum, BO, van der Kolk, BA, et al.Multicenter, double-blind comparison of sertraline and placebo in the treatment of post-traumatic stress disorder. Arch Gen Psychiatry. 2001;58:485–492.CrossRefGoogle Scholar
20.Connor, KM, Davidson, JR, Potts, NL, et al.Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998;18:373–378.CrossRefGoogle ScholarPubMed
21.Hair, T, Castrogiovanni, P, Domenech, J, et al.Short-term efficacy of paroxetine in social anxiety disorder is maintained after long-term treatment. Int J Neuropsychopharmacol. 2000;3:S227.Google Scholar
22.Kumar, R, Pitts, C, Carpenter, D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder. Eur Neuropsychopharmacol. 1999;9:S312.CrossRefGoogle Scholar
23.Walker, JR, Van Ameringen, MA, Swinson, R, et al.Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20:636–644.CrossRefGoogle ScholarPubMed
24.Blomhoff, S, Haug, TT, Hellstrom, K, et al.Randomised control general practice trial of sertraline, exposure and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23–30.CrossRefGoogle Scholar
25.Rickels, K, Schweizer, E, Csanalosi, I, et al.Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45:444–450.CrossRefGoogle ScholarPubMed
26.Allgulander, C, Hackett, D, Salinas, E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15–22.CrossRefGoogle Scholar
27.Gelenberg, AJ, Lydiard, RB, Rudolph, RL, et al.Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082–3088.CrossRefGoogle ScholarPubMed
28.Stocchi, F, Nordera, G, Jokinen, R, Lepola, U. Efficacy and tolerability of paroxetine for the long-term treatment of generalised anxiety disorder (GAD). Abstract presented at: Annual Meeting of the American Psychiatric Association; May 5–10, 2001; New Orleans, La.CrossRefGoogle Scholar